Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015. Diabetes Care 2021, 44: e137-e138. PMID: 34016610, PMCID: PMC8247494, DOI: 10.2337/dci21-0009.Commentaries, Editorials and LettersAssociations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes
Ding Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes. 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.Peer-Reviewed Original Research